PL1709014T3 - Przeciwcukrzycowe oksazolidenodiony i tiazolidenodiony - Google Patents
Przeciwcukrzycowe oksazolidenodiony i tiazolidenodionyInfo
- Publication number
- PL1709014T3 PL1709014T3 PL05722436T PL05722436T PL1709014T3 PL 1709014 T3 PL1709014 T3 PL 1709014T3 PL 05722436 T PL05722436 T PL 05722436T PL 05722436 T PL05722436 T PL 05722436T PL 1709014 T3 PL1709014 T3 PL 1709014T3
- Authority
- PL
- Poland
- Prior art keywords
- thiazolidinediones
- diones
- diabetes
- type
- oxazolidinediones
- Prior art date
Links
- 229940123464 Thiazolidinedione Drugs 0.000 title 1
- 230000003178 anti-diabetic effect Effects 0.000 title 1
- 239000003472 antidiabetic agent Substances 0.000 title 1
- 150000001475 oxazolidinediones Chemical class 0.000 title 1
- 150000001467 thiazolidinediones Chemical class 0.000 title 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 150000001473 2,4-thiazolidinediones Chemical class 0.000 abstract 1
- PQBVPYCBEZESNR-UHFFFAOYSA-N 3-benzyl-5-phenoxy-1,3-oxazolidine-2,4-dione Chemical class O=C1N(CC=2C=CC=CC=2)C(=O)OC1OC1=CC=CC=C1 PQBVPYCBEZESNR-UHFFFAOYSA-N 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 102000000536 PPAR gamma Human genes 0.000 abstract 1
- 108010016731 PPAR gamma Proteins 0.000 abstract 1
- -1 Phenoxyphenyl Chemical group 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 208000006575 hypertriglyceridemia Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000004031 partial agonist Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/44—Two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/62—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems having two or more ring systems containing condensed 1,3-oxazole rings
- C07D263/64—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems having two or more ring systems containing condensed 1,3-oxazole rings linked in positions 2 and 2' by chains containing six-membered aromatic rings or ring systems containing such rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53763004P | 2004-01-20 | 2004-01-20 | |
| PCT/US2005/001344 WO2005070905A1 (en) | 2004-01-20 | 2005-01-18 | Antidiabetic oxazolidinediones and thiazolidinediones |
| EP05722436A EP1709014B1 (en) | 2004-01-20 | 2005-01-18 | Antidiabetic oxazolidinediones and thiazolidinediones |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1709014T3 true PL1709014T3 (pl) | 2007-10-31 |
Family
ID=34807112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL05722436T PL1709014T3 (pl) | 2004-01-20 | 2005-01-18 | Przeciwcukrzycowe oksazolidenodiony i tiazolidenodiony |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20070173434A1 (pl) |
| EP (1) | EP1709014B1 (pl) |
| JP (1) | JP2007518803A (pl) |
| KR (1) | KR20060128921A (pl) |
| CN (1) | CN100451008C (pl) |
| AT (1) | ATE363475T1 (pl) |
| AU (1) | AU2005206540B2 (pl) |
| BR (1) | BRPI0506919A (pl) |
| CA (1) | CA2553405A1 (pl) |
| CY (1) | CY1106757T1 (pl) |
| DE (1) | DE602005001265T2 (pl) |
| DK (1) | DK1709014T3 (pl) |
| ES (1) | ES2287908T3 (pl) |
| IL (1) | IL176878A0 (pl) |
| MX (1) | MXPA06008190A (pl) |
| NO (1) | NO20063720L (pl) |
| NZ (1) | NZ548556A (pl) |
| PL (1) | PL1709014T3 (pl) |
| PT (1) | PT1709014E (pl) |
| RU (1) | RU2355682C2 (pl) |
| WO (1) | WO2005070905A1 (pl) |
| ZA (1) | ZA200605512B (pl) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006138328A1 (en) * | 2005-06-14 | 2006-12-28 | Merck & Co., Inc. | Process for the production of antidiabetic oxazolidinediones |
| CA2612765A1 (en) | 2005-07-06 | 2007-01-18 | Merck And Co., Inc. | Antidiabetic oxazolidinediones and thiazolidinediones |
| JP2009502783A (ja) * | 2005-07-20 | 2009-01-29 | メルク エンド カムパニー インコーポレーテッド | 抗糖尿病性オキサゾリジンジオン及びチアゾリジンジオン |
| WO2008096769A1 (ja) * | 2007-02-08 | 2008-08-14 | Daiichi Sankyo Company, Limited | 置換されたセルコスポラミド誘導体を含有する医薬 |
| US20160331729A9 (en) | 2007-04-11 | 2016-11-17 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| US11241420B2 (en) | 2007-04-11 | 2022-02-08 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| MY203360A (en) | 2018-06-06 | 2024-06-26 | Metavant Sciences Gmbh | Methods of treating subjects having diabetes with chronic kidney disease |
| CA3103324A1 (en) | 2018-06-14 | 2019-12-19 | Poxel | Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes |
| CN111892569A (zh) * | 2019-05-05 | 2020-11-06 | 石家庄圣泰化工有限公司 | 4,4’-联-1,3-二氧戊环-2,2’-二酮的合成方法 |
| CN112898265A (zh) * | 2019-11-18 | 2021-06-04 | 石家庄圣泰化工有限公司 | 4,4’-联-1,3-二氧戊环-2,2’-二酮的制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW268952B (pl) * | 1993-02-26 | 1996-01-21 | Takeda Pharm Industry Co Ltd | |
| JPH07138258A (ja) * | 1993-11-16 | 1995-05-30 | Taiho Yakuhin Kogyo Kk | チアゾリジンジオン誘導体又はその塩 |
| US6114526A (en) * | 1996-07-01 | 2000-09-05 | Dr. Reddy's Research Foundation | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases |
| ID24878A (id) * | 1997-12-19 | 2000-08-31 | Merck & Co Inc | Turunan ariltiazolidinedion |
| WO2003018135A1 (en) * | 2001-08-24 | 2003-03-06 | Wyeth Holdings Corporation | Method of using 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase |
-
2005
- 2005-01-18 DE DE602005001265T patent/DE602005001265T2/de not_active Expired - Fee Related
- 2005-01-18 CN CNB2005800027164A patent/CN100451008C/zh not_active Expired - Fee Related
- 2005-01-18 ES ES05722436T patent/ES2287908T3/es not_active Expired - Lifetime
- 2005-01-18 DK DK05722436T patent/DK1709014T3/da active
- 2005-01-18 WO PCT/US2005/001344 patent/WO2005070905A1/en not_active Ceased
- 2005-01-18 MX MXPA06008190A patent/MXPA06008190A/es active IP Right Grant
- 2005-01-18 AU AU2005206540A patent/AU2005206540B2/en not_active Ceased
- 2005-01-18 NZ NZ548556A patent/NZ548556A/en unknown
- 2005-01-18 KR KR1020067014509A patent/KR20060128921A/ko not_active Withdrawn
- 2005-01-18 PL PL05722436T patent/PL1709014T3/pl unknown
- 2005-01-18 AT AT05722436T patent/ATE363475T1/de not_active IP Right Cessation
- 2005-01-18 BR BRPI0506919-0A patent/BRPI0506919A/pt not_active IP Right Cessation
- 2005-01-18 RU RU2006129930/04A patent/RU2355682C2/ru active
- 2005-01-18 PT PT05722436T patent/PT1709014E/pt unknown
- 2005-01-18 US US10/586,976 patent/US20070173434A1/en not_active Abandoned
- 2005-01-18 EP EP05722436A patent/EP1709014B1/en not_active Expired - Lifetime
- 2005-01-18 CA CA002553405A patent/CA2553405A1/en not_active Abandoned
- 2005-01-18 JP JP2006551178A patent/JP2007518803A/ja not_active Withdrawn
-
2006
- 2006-07-04 ZA ZA200605512A patent/ZA200605512B/en unknown
- 2006-07-16 IL IL176878A patent/IL176878A0/en unknown
- 2006-08-18 NO NO20063720A patent/NO20063720L/no not_active Application Discontinuation
-
2007
- 2007-07-24 CY CY20071100991T patent/CY1106757T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0506919A (pt) | 2007-06-05 |
| ES2287908T3 (es) | 2007-12-16 |
| CA2553405A1 (en) | 2005-08-04 |
| ATE363475T1 (de) | 2007-06-15 |
| ZA200605512B (en) | 2007-11-28 |
| CN1910163A (zh) | 2007-02-07 |
| NZ548556A (en) | 2009-03-31 |
| WO2005070905A1 (en) | 2005-08-04 |
| EP1709014A1 (en) | 2006-10-11 |
| MXPA06008190A (es) | 2006-08-31 |
| RU2006129930A (ru) | 2008-02-27 |
| KR20060128921A (ko) | 2006-12-14 |
| DE602005001265T2 (de) | 2008-01-31 |
| DK1709014T3 (da) | 2007-09-10 |
| CN100451008C (zh) | 2009-01-14 |
| AU2005206540A1 (en) | 2005-08-04 |
| NO20063720L (no) | 2006-10-09 |
| JP2007518803A (ja) | 2007-07-12 |
| PT1709014E (pt) | 2007-08-13 |
| EP1709014B1 (en) | 2007-05-30 |
| DE602005001265D1 (de) | 2007-07-12 |
| IL176878A0 (en) | 2006-10-31 |
| RU2355682C2 (ru) | 2009-05-20 |
| US20070173434A1 (en) | 2007-07-26 |
| CY1106757T1 (el) | 2012-05-23 |
| AU2005206540B2 (en) | 2009-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004066963A3 (en) | N-cyclohexylaminocarbonyl benzenesulfonamide derivatives | |
| WO2004019869A3 (en) | Indoles having anti-diabetic activity | |
| IL176878A0 (en) | Antidiabetic oxazolidinediones and thiazolidinediones | |
| CA2495943A1 (en) | Indoles having anti-diabetic activity | |
| MY135758A (en) | Oxa-and thiazolidinedione hypoglycemic and hypocholesterolemic agents | |
| NI200700200A (es) | Compuestos aromáticos fusionados con actividad anti-diabética | |
| MX2008011123A (es) | Benzotiazoles que tienen actividad de receptor h3 de histamina. | |
| AP2005003261A0 (en) | Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors. | |
| WO2006127503A3 (en) | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders | |
| Blaschke et al. | Vascular effects of TZDs: new implications | |
| BR0211414A (pt) | Composto, uso do mesmo, composição farmacêutica, e, métodos para o tratamento e/ou prevenção de condições mediadas pelos receptores nucleares e de diabetes tipo i, diabetes tipo ii, tolerância à glicose, resistência à insulina ou obesidade prejudicadas | |
| ATE405260T1 (de) | Thiazol- und oxazolderivaten als ppar modulatoren | |
| WO2006014262A3 (en) | Indoles having anti-diabetic activity | |
| ATE421490T1 (de) | Verwendung von polymerpulver in pflasterfugenmörteln | |
| ATE352545T1 (de) | Arylthiazolidindion-derivate | |
| WO2007018956A3 (en) | Antidiabetic oxazolidinediones and thiazolidinediones | |
| WO2006022954A3 (en) | Benzoureas having anti-diabetic activity | |
| DE60333211D1 (de) | Neue verbindungen und deren verwendung als ppar-modulatoren | |
| DK1789403T3 (da) | N-(phenyl-oxazol-4ylmethoxymethyl)-cyclohexyl-ravsyreamid derivater og beslægtede forbindelser som PPAR-ligander (peroxisom-proliferator-aktiverede receptorer) til behandling af hyperlipidæmi og diabetes | |
| ATE515494T1 (de) | Neue verbindungen, deren herstellung und verwendung | |
| CO5170420A1 (es) | Nuevos farmacos hidrocloruro | |
| MY139550A (en) | Indoles having anti-diabetic activity | |
| DE602005022585D1 (de) | Phenoxyessigsäurederivate als ppar-agonisten | |
| DE602005024539D1 (de) | Neue verbindungen, ihre herstellung und verwendung | |
| MXPA05013034A (es) | N-alquinil-2-heteroariloxialquilamidas para uso como fungicidas. |